ERBB2 and gastric cancer: Although the addition of trastuzumab to chemotherapy significantly prolonged survival in patients with ERBB2-overexpressing breast or gastric cancers (Piccart-Gebhart et al., 2005; Romond et al., 2005; Joensuu et al., 2006; Bang et al., 2010), these clinical benefits failed to translate in improved survival of patients with ERBB2-overexpressing non-small cell lung cancers (NSCLCs) (Gatzemeier et al., 2004; Langer et al., 2004).